· Trials · Trials Desk
Lilly's triple GLP-1/GIP/glucagon agonist delivers the deepest Phase 3 weight loss yet, with parallel benefits in knee OA and OSA. NCT04881760, NCT06662383.
This brief is part of the Novusyn Research news desk. We track peptide clinical readouts, regulatory actions, and pharma developments in neutral, evidence-led language for scientifically literate readers.
For related context, see the full news desk, clinical trials tracker, regulation tracker, compound directory, and guides library.